

Prestige BioPharma’s Sputnik Light CMO Project Going Along as Planned

Singapore, [12 January 2022] / Prestige BioPharma Limited (PBP, 950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, announced that the company’s Sputnik Light CMO project is going along as initially planned, amid Omicron spread.

PBP signed a contract manufacturing agreement to produce Russia’s Sputnik Light COVID19 vaccine in November last year. The demands of Sputnik Light are expected to grow rapidly as both Sputnik V (Ad26/Ad5 vector) and Sputnik Light (Ad26 vector) use Sputnik Light as a booster shot.

According to the recent study of Russia’s Gamaleya National Research Center of Epidemiology and Microbiology, the expected efficacy of Sputnik V with Sputnik Light booster against Omicron infection could be more than 80%. Russia also mentioned that the study of reputed Harvard team demonstrated that boosting of Pfizer vaccine with Ad26 vector produces optimal durable protection against Omicron.

Currently, Sputnik V and Sputnik Light have been approved in more than 70 countries and in around 30 countries respectively, and PBP’s commercial production of both vaccines are planned to be commenced soon.

PBP’s global-scale vaccine center in Korea with 104,000 liters of production capacity has been designed with multi-purpose production lines using Prestige Biologics (334970: KOSDAQ)’ proprietary technology, ALITA Smart BioFactory™, so the production facility can anytime be used for PBP’s other pipeline production such as antibody therapeutics.

PBP’s CEO, Dr Lisa S. Park commented: “Currently, a considerable number of reputed studies are demonstrating the efficacy of Sputnik Light as a booster shot against Omicron infection and our production volume is also expected to increase due to its high demand” and “in 2022, PBP will prove our true potential and value to the market with visible performance and revenue from the existing pipeline and vaccine business”.